Role of biomarkers in cardiac structure phenotyping in heart failure with preserved ejection fraction: Critical appraisal and practical use

European Journal of Heart Failure

Volumn 17, Issue 12, 2015, Pages 1231-1239

  D'Elia, Emilia ^a   Vaduganathan, Muthiah ^b   Gori, Mauro ^a   Gavazzi, Antonello ^a   Butler, Javed ^c   Senni, Michele ^a  

^a Azienda Ospedaliera Papa Giovanni XXIII   (Italy)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c STONY BROOK UNIVERSITY   (United States)

Author keywords

Biomarkers; Cardiac structure phenotypes; Heart failure with preserved ejection fraction

Indexed keywords

ADRENOMEDULLIN; ADVANCED GLYCATION END PRODUCT; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BIOLOGICAL MARKER; C REACTIVE PROTEIN; GALECTIN 3; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 1; INTERLEUKIN 6; METFORMIN; MICRORNA; MINERALOCORTICOID ANTAGONIST; RANOLAZINE; SACUBITRIL PLUS VALSARTAN; TROPONIN; TUMOR NECROSIS FACTOR ALPHA; NATRIURETIC FACTOR;

CORONARY ARTERY DISEASE; DIAGNOSTIC VALUE; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART HYPERTROPHY; HEART MUSCLE FIBROSIS; HEART VENTRICLE REMODELING; HOSPITALIZATION; HUMAN; MORTALITY; MYOCARDITIS; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PHENOTYPIC VARIATION; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; HEART FAILURE; HEART STROKE VOLUME; PATHOLOGY; PHENOTYPE;

BIOMARKERS; HEART FAILURE; HUMANS; NATRIURETIC PEPTIDES; PHENOTYPE; STROKE VOLUME;

EID: 84949524331     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1002/ejhf.430     Document Type: Review

References (98)

1. McMurray JJ, Pfeffer MA,. Heart failure. Lancet 2005; 365: 1877-1889.
2. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, Køber L, Lip GY, Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, Rønnevik PK, Rutten FH, Schwitter J, Seferovic P, Stepinska J, Trindade PT, Voors AA, Zannad F, Zeiher A,; Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2012; 14: 803-806.
3. Ambrosy AP, Fonarow GC, Butler J, Chioncel O, Greene SJ, Vaduganathan M, Nodari S, Lam CS, Sato N, Shah AN, Gheorghiade M,. The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries. J Am Coll Cardiol 2014; 63: 1123-1133.
4. Fonarow GC, Stough WG, Abraham WT, Albert NM, Gheorghiade M, Greenberg BH, O'Connor CM, Sun JL, Yancy CW, Young JB,. OPTIMIZE-HF Investigators and Hospitals. Influence of beta-blocker continuation or withdrawal on outcomes in patients hospitalized with heart failure: findings from the OPTIMIZE-HF program. J Am Coll Cardiol 2007; 50: 768-777.
5. Senni M, Gavazzi A, Oliva F, Mortara A, Urso R, Pozzoli M, Metra M, Lucci D, Gonzini L, Cirrincione V, Montagna L, Di Lenarda A, Maggioni AP, Tavazzi L,; IN HF Outcome Investigators. In-hospital and 1-year outcomes of acute heart failure patients according to presentation (de novo vs. worsening) and ejection fraction. Results from IN-HF Outcome Registry. Int J Cardiol 2014; 173: 163-169.
6. Butler J, Fonarow GC, Zile MR, Lam CS, Roessig L, Schelbert EB, Shah SJ, Ahmed A, Bonow RO, Cleland JG, Cody RJ, Chioncel O, Collins SP, Dunnmon P, Filippatos G, Lefkowitz MP, Marti CN, McMurray JJ, Misselwitz F, Nodari S, O'Connor C, Pfeffer MA, Pieske B, Pitt B, Rosano G, Sabbah HN, Senni M, Solomon SD, Stockbridge N, Teerlink JR, Georgiopoulou VV, Gheorghiade M,. Developing therapies for heart failure with preserved ejection fraction: current state and future directions. JACC Heart Fail 2014; 2: 97-112.
7. Shah S, Katz D, Deo RC,. Phenotypic spectrum of heart failure with preserved ejection fraction. Heart Fail Clin 2014; 10: 407-418.
8. Senni M, Paulus WJ, Gavazzi A, Fraser AG, Díez J, Solomon SD, Smiseth OA, Guazzi M, Lam CS, Maggioni AP, Tschöpe C, Metra M, Hummel SL, Edelmann F, Ambrosio G, Stewart Coats AJ, Filippatos GS, Gheorghiade M, Anker SD, Levy D, Pfeffer MA, Stough WG, Pieske BM,. New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes. Eur Heart J 2014; 35: 2797-2815.
9. Butler J, Fonarow GC, Zile MR, Lam CS, Roessig L, Schelbert EB, Shah SJ, Ahmed A, Bonow RO, Cleland JG, Cody RJ, Chioncel O, Collins SP, Dunnmon P, Filippatos G, Lefkowitz MP, Marti CN, McMurray JJ, Misselwitz F, Nodari S, O'Connor C, Pfeffer MA, Pieske B, Pitt B, Rosano G, Sabbah HN, Senni M, Solomon SD, Stockbridge N, Teerlink JR, Georgiopoulou VV, Gheorghiade M,. Developing therapies for heart failure with preserved ejection fraction: current state and future directions. JACC Heart Fail 2014; 2: 97-112.
10. Senni M, Gavazzi A, Gheorghiade M, Butler J., Heart failure at crossroads. Moving beyond blaming stakeholders to targeting the heart. Eur J Heart Fail 2015; doi: 10.1002/ejhf.315.
11. Passino C, Barison A, Vergaro G, Gabutti A, Borrelli C, Emdin M, Clerico AG,. Markers of fibrosis, inflammation, and remodeling pathways in heart failure. Clin Chim Acta 2015; 443: 29-38.
12. Cheng JM, Akkerhuis KM, Battes LC, van Vark LC, Hillege HL, Paulus WJ, Boersma E, Kardys I,. Biomarkers of heart failure with normal ejection fraction: a systematic review. Eur J Heart Fail 2013; 15: 1350-1362.
13. De Boer RA, Daniels BD, Maisel AS, Jannuzzi JL,. State of the art: newer biomarkers in heart failure. Eur J Heart Fail 2015; 17: 559-569.
14. Mohammed SF, Hussain S, Mirzoyev SA, Edwards WD, Maleszewski JJ, Redfield MM,. Coronary microvascular rarefaction and myocardial fibrosis in heart failure with preserved ejection fraction. Circulation 2015; 131: 550-559.
15. Zile MR, Gottdiener JS, Hetzel SJ, McMurray JJ, Komaida M, McKelvie R, Baicu CF, Massie BM, Carson PE,. I PRESERVE Investigators. Prevalence and significance of alterations in cardiac structure and function in patients with heart failure and preserved ejection fraction. Circulation 2011; 124: 2491-2501.
16. Shah AM,. Ventricular remodeling in heart failure with preserved ejection fraction. Curr Heart Fail Rep 2013; 10: 341-349.
17. Shah AM, Shah SJ, Anand IS, Sweitzer NK, O'Meara E, Heitner JF, Sopko G, Li G, Assmann SF, McKinlay SM, Pitt B, Pfeffer MA, Solomon SD,; TOPCAT Investigators. Cardiac structure and function in heart failure with preserved ejection fraction: baseline findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist trial. Circ Heart Fail 2014; 7: 104-115.
18. Zile MR, Baicu CF, Gaasch WH,. Diastolic heart failure abnormalities in active relaxation and passive stiffness of the left ventricle. N Engl J Med 2004; 350: 1953-1959.
19. Zile MR, Gottdiener JS, Hetzel SJ, McMurray JJ, Komajda M, McKelvie R, Baicu CF, Massie BM, Carson PE,. Prevalence and significance of alterations in cardiac structure and function in patients with heart failure and a preserved ejection fraction. Circulation 2011; 124: 2491-2501.
20. Shah AM, Pfeffer MA,. The many faces of heart failure with preserved ejection fraction. Nat Rev Cardiol 2012; 9: 555-556.
21. Gori M, Senni M, Gupta DK, Charytan DM, Kraigher-Krainer E, Pieske B, Claggett B, Shah AM, Santos AB, Zile MR, Voors AA, McMurray JJ, Packer M, Bransford T, Lefkowitz M, Solomon SD,; PARAMOUNT Investigators. Association between renal function and cardiovascular structure and function in heart failure with preserved ejection fraction. Eur Heart J 2014; 35: 3442-3451.
22. Schwartz PJ, De Ferrari GM,. Sympathetic-parasympathetic interaction in health and disease: abnormalities and relevance in heart failure. Heart Fail Rev 2011; 16: 101-107.
23. Nishi EE, Bergamaschi CT, Campos RR,. The crosstalk between the kidney and the central nervous system: the role of renal nerves in blood pressure regulation. Exp Physiol 2015; 100: 479-484.
24. Metra M, Lombardi C,. Renin-angiotensin system blockade and worsening renal function in heart failure: an unfinished story. J Am Coll Cardiol 2014; 64: 1114-1116.
25. Goldsmith SR,. Interactions between the sympathetic nervous system and the RAAS in heart failure. Current Heart Fail Rep 2004; 12: 45-50.
26. Hogg K, McMurray J,. Neurohumoral pathways in heart failure with preserved systolic function. Prog Cardiovasc Dis 2005; 47: 357-366.
27. Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJV, Michelson EL, Olofsson B, Ostergren J,. for the CHARM investigators and committees. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003; 362: 777-781.
28. Cleland JGF, Tendera M, Adamus J, Freemantle N, Polonski L, Taylor J,. on behalf of PEP-CHF investigators. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J 2006; 27: 2338-2345.
29. Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR, Anderson S, Donovan M, Iverson E, Staiger C, Ptaszynska A,. for the I-PRESERVE investigators. New Engl J Med 2008; 359: 2456-2467.
30. Paulus WJ, van Ballegoij JJ,. Treatment of heart failure with normal ejection fraction: an inconvenient truth! J Am Coll Cardiol 2010; 55: 526-537.
31. Edelmann F, Wachter R, Schmidt AG, Kraigher-Krainer E, Colantonio C, Kamke W, Duvinage A, Stahrenberg R, Durstewitz K, Loffler M, Dungen HD, Tschope C, Herrmann-Lingen C, Halle M, Hasenfuss G, Gelbrich G, Pieske B,. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: The ALDO-DHF randomized controlled trial. JAMA 2013; 209: 781-791.
32. Shah AM, Claggett B, Sweitzer NK, Shah SJ, Anand IS, O'Meara E, Desai AS, Heitner JF, Li G, Fang J, Rouleau J, Zile MR, Markov V, Ryabov V, Reis G, Assmann SF, McKinlay SM, Pitt B, Pfeffer MA, Solomon SD,. Cardiac structure and function and prognosis in heart failure with preserved ejection fraction: findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) Trial. Circ Heart Fail 2014; 7: 740-751.
33. Gu J, Noe A, Chandra P, Al-Fayoumi S, Ligueros-Saylan M, Sarangapani R, Maahs S, Ksander G, Rigel DF, Jeng AY, Lin TH, Zheng W, Dole WP,. Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi). J Clin Pharmacol 2010; 50: 401-414.
34. Solomon SD, Zile M, Pieske B, Voors A, Shah A, Kraigher-Krainer E, ShiV, BransfordT, Takeuchi M, Gong J, Lefkowitz M, Packer M, McMurray JJ,. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet 2012; 380: 1387-1395.
35. Krum H., Prospective Comparison of ARNi With ACE-I to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF). Circulation 2015; 131: 11-12.
36. Zile MR, Baicu CF,. Biomarkers of diastolic dysfunction and myocardial fibrosis: application to heart failure with a preserved ejection fraction. J Cardiovasc Transl Res 2013; 6: 501-515.
37. Zile MR, Baicu CF, Ikonomidis JS, Stroud RE, Nietert PJ, Bradshaw AD, Slater R, Palmer BM, Van Buren P, Meyer M, Redfield MM, Bull DA, Granzier HL, LeWinter MM,. Myocardial stiffness in patients with heart failure and a preserved ejection fraction: contributions of collagen and titin. Circulation 2015; 131: 1247-1259.
38. Martos R, Baugh J, Ledwidge M, O'Loughlin C, Murphy NF, Conlon C, Patle A, Donnelly SC, McDonald K,. Diastolic heart failure: evidence of increased myocardial collagen turnover linked to diastolic dysfunction. Circulation 2007; 115: 888-895.
39. Ahmad T, Fiuzat M, Neely B, Neely ML, Pencina MJ, Kraus WE, Zannad F, Whellan DJ, Donahue MP, Piña IL, Adams KF, Kitzman DW, O'Connor CM, Felker GM,. Biomarkers of myocardial stress and fibrosis as predictors of mode of death in patients with chronic heart failure. JACC Heart Fail 2014; 2: 260-268.
40. Su MY, Lin LY, Tseng YH, Chang CC, Wu CK, Lin JL, Tseng WY,. CMR-verified diffuse myocardial fibrosis is associated with diastolic dysfunction in HFpEF. JACC Cardiovasc Imaging 2014; 7: 991-997.
41. Van Heerebeek L, Borbely A, Niessen HW, Bronzwaer JG, van der Velden J, Stienen GJ, Linke WA, Laarman GJ, Paulus WJ,. Myocardial structure and function differ in systolic and diastolic heart failure. Circulation 2006; 113: 1966-1973.
42. van Heerebeek L, Hamdani N, Handoko ML, Falcao-Pires I, Musters RJ, Kupreishvili K, Ijsselmuiden AJ, Schalkwijk CG, Bronzwaer JG, Diamant M, Borbely A, van der Velden J, Stienen GJ, Laarman GJ, Niessen HW, Paulus WJ,. Diastolic stiffness of the failing diabetic heart: importance of fibrosis, advanced glycation end products, and myocyte resting tension. Circulation 2008; 117: 43-51.
43. Aoki T, Fukumoto Y, Sugimura K, Oikawa M, Satoh K, Nakano M, Nakayama M, Shimokawa H,. Prognostic impact of myocardial interstitial fibrosis in non-ischemic heart failure. Comparison between preserved and reduced ejection fraction heart failure. Circ J 2011; 75: 2605-2613.
44. Bhardwaj, A, Januzzai, JL,. ST 2: a novel biomarker for heart failure. Expert Rev Mol Diagn 2010; 10: 459-464.
45. Yang RY, Rabinovich GA, Liu FT,. Galectins: Structure, function and therapeutic potential. Expert Rev Mol Med 2008; 13: e17-39.
46. de Boer R, A Lok D, Jaarsma T, van der Meer P, Voors AA, Hillege HL, van Veldhuisen VJ,. Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Ann Med 2011; 43: 60-66.
47. Edelmann F, Holzendorf V, Wachter R, Nolte K, Schmidt AG, Kraigher-Krainer E, Duvinage A, Unkelbach I, Düngen HD, Tschöpe C, Herrmann-Lingen C, Halle M, Hasenfuss G, Gelbrich G, Stough WG, Pieske BM,. Galectin-3 in patients with heart failure with preserved ejection fraction: results from the Aldo-DHF trial. Eur J Heart Fail 2015; 17: 214-223.
48. Strivatsan V, George M, Shanmugam E,. Utility of galectin-3 as a prognostic biomarker in heart failure: where do we stand? Eur J Prev Cardiol 2015; 22: 1096-1110.
49. van der Velde AR, Gullestad L, Ueland T, Aukrust P, Guo Y, Adourian A, Muntendam P, van Veldhuisen DJ, de Boer RA,. Prognostic value of changes in galectin-3 levels over time in patients with heart failure: data from CORONA and COACH. Circ Heart Fail 2013; 6: 219-226.
50. AbouEzzeddine OF, Haines P, Stevens S, Nativi-Nicolau J, Felker GM, Borlaug BA, Chen HH, Tracy RP, Braunwald E, Redfield MM,. Galectin-3 in heart failure with preserved ejection fraction. A RELAX trial substudy (Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in Diastolic Heart Failure). JACC Heart Fail 2015; 3: 245-252.
51. Meijers WC, Januzzi JL, deFilippi C, Adourian AS, Shah SJ, van Veldhuisen DJ, de Boer RA,. Elevated plasma galectin-3 is associated with near-term rehospitalization in heart failure: a pooled analysis of 3 clinical trials. Am Heart J 2014; 167: 853-860.
52. Shah RV, Januzzi JL,. ST2: a novel remodeling biomarker in acute and chronic heart failure. Curr Heart Fail 2010; 1: 9-14
53. Xu SD, Su GH, Lu YX, Shuai XX, Tao XF, Meng YD, Luo P,. Elevated soluble ST2 and depression increased the risk of all-cause mortality and hospitalization in patients with heart failure. Int Heart J 2014; 55: 445-450.
54. Shah KS, Maisel AS,. Novel biomarkers in heart failure with preserved ejection fraction. Heart Fail Clin 2014; 10: 471-479.
55. Friões F, Lourenço P, Laszczynska O, Almeida PB, Guimarães JT, Januzzi JL, Azevedo A, Bettencourt P,. Prognostic value of sST2 added to BNP in acute heart failure with preserved or reduced ejection fraction. Clin Res Cardiol 2015; 104: 491-499.
56. Manzano-Fernández S, Mueller T, Pascual-Figal D, Truong QA, Januzzi JL,. Usefulness of soluble concentrations of interleukin family member ST2 as predictor of mortality in patients with acutely decompensated heart failure relative to left ventricular ejection fraction. Am J Cardiol 2011; 107: 259-267.
57. Wang YC, Yu CC, Chiu FC, Tsai CT, Lai LP, Hwang JJ, Lin JL,. Soluble ST2 as a biomarker for detecting stable heart failure with a normal ejection fraction in hypertensive patients. J Card Fail 2013; 19: 163-168.
58. Lijnen P, Petrov V,. Induction of cardiac fibrosis by aldosterone. J Mol Cell Cardiol 2000; 32: 865-879.
59. Pfeffer MA, Pitt B, McKinlay SM,. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 2014; 371: 181-182.
60. Borlaug BA, Paulus WJ,. Heart failure with preserved ejection fraction: pathophysiology, diagnosis and treatment. Eur Heart J 2011; 32: 670-679.
61. Paulus WJ, Tschöpe C,. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol 2013; 23: 263-271.
62. Paulus WJ,. Cytokines and heart failure. Heart Fail Monit 2000; 1: 50-56.
63. Putko BN, Wang Z, Lo J, Anderson T, Becher H, Dyck JR, Kassiri Z, Oudit GY,; Alberta HEART Investigators. Circulating levels of tumor necrosis factor-alpha receptor 2 are increased in heart failure with preserved ejection fraction relative to heart failure with reduced ejection fraction: evidence for a divergence in pathophysiology. PLoS One 2014; 9: e99495
64. Collier P, Watson CJ, Voon V, Phelan D, Jan A, Mak G, Martos R, Baugh JA, Ledwidge MT, McDonald KM,. Can emerging biomarkers of myocardial remodelling identify asymptomatic hypertensive patients at risk for diastolic dysfunction and diastolic heart failure? Eur J Heart Fail 2011; 13: 1087-1095.
65. Haass M, Kitzman DW, Anand IS, Miller A, Zile MR, Massie BM, Carson PE,. Body mass index and adverse cardiovascular outcomes in heart failure patients with preserved ejection fraction: results from the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial. Circ Heart Fail 2011; 4: 324-331.
66. Little WC, Zile MR, Kitzman DW, Hundley WG, O'Brien TX, Degroof RC,. The effect of Alagebrium Chloride (ALT-711), a novel glucose cross-link breaker, in the treatment of elderly patients with diastolic heart failure. J Cardiac Fail 2005; 11: 191-195.
67. Ladeiras-Lopes R, Fontes-Carvalho R, Bettencourt N, Sampaio F, Gama V, Leite-Moreira A,. Novel therapeutic targets of metformin: metabolic syndrome and cardiovascular disease. Expert Opin Ther Targets 2015; 19: 869-877.
68. Ladeiras-Lopes R, Fontes-Carvalho R, Bettencourt N, Sampaio F, Gama V, Leite-Moreira AF,. METformin in DIastolic Dysfunction of MEtabolic syndrome (MET-DIME) trial: rationale and study design: MET-DIME trial. Cardiovasc Drugs Ther 2014; 28: 191-196.
69. Nochioka K, Sakata Y, Miyata S, Miura M, Takada T, Tadaki S, Ushigome R, Yamauchi T, Takahashi J, Shimokawa H,; CHART-2 Investigators. Prognostic impact of statin use in patients with heart failure and preserved ejection fraction. Circ J 2015; 79: 574-582.
70. Pinchuk TV, Fedulaev YN, Khairetdinova GA, Denisova NN, Chura OV, Logunova IY,. Anti-inflammatory effects of simvastatin in patients with chronic heart failure. Bull Exp Biol Med 2014; 157: 552-554.
71. Hwang SJ, Melenovsky V, Borlaug BA,. Implications of coronary artery disease in heart failure with preserved ejection fraction. J Am Coll Cardiol 2014; 63: 2817-2827.
72. Rusinaru D, Houpe D, Szymanski C, Levy F, Marechaux S, Triboulloy C,. Coronary artery disease and 10-year outcome after hospital admission for heart failure with preserved and reduced ejection fraction. Eur J Heart Fail 2014; 16: 967-976.
73. Mohammed SF, Borlaug BA, Roger VL, Mirzoyev SA, Rodeheffer RJ, Chirinos JA, Redfield MM,. Comorbidity and ventricular and vascular structure and function in heart failure with preserved ejection fraction: a community-based study. Circ Heart Fail 2012; 5: 710-719.
74. de Lemos JA, Drazner MH, Omland T, Ayers CR, Khera A, Rohatgi A, Hashim I, Berry JD, Das SR, Morrow DA, McGuire DK,. Association of troponin T detected with a highly sensitive assay and cardiac structure and mortality risk in the general population. JAMA 2010; 304: 2503-2512
75. Sato Y, Taniguchi R, Makiyama T, Nagai K, Okada H, Yamada T, Matsumori A, Takatsu Y,. Serum cardiac troponin T and plasma brain natriuretic peptide in patients with cardiac decompensation. Heart 2002; 88: 647-648.
76. Perna ER, Macin SM, Canella JP, Augier N, Stival JL, Cialzeta JR, Pitzus AE, Garcia EH, Obregõn R, Brizuela M, Barbagelata A,. Ongoing myocardial injury in stable severe heart failure: value of cardiac troponin T monitoring for high-risk patient identification. Circulation 2004; 110: 2376-2382.
77. Biolo A, Fisch M, Balog J, Chao T, Schulze PC, Ooi H, Siwik D, Colucci WS,. J. Episodes of acute heart failure syndrome are associated with increased levels of troponin and extracellular matrix markers. Circ Heart Fail 2010; 3: 44-50.
78. Greenberg B., Heart failure preserved ejection fraction with coronary artery disease: time for a new classification? J Am Coll Cardiol 2014; 63: 2828-2830.
79. Packer M, McMurray JJ, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile M, Andersen K, Arango JL, Arnold JM, Bělohlávek J, Böhm M, Boytsov S, Burgess LJ, Cabrera W, Calvo C, Chen CH, Dukat A, Duarte YC, Erglis A, Fu M, Gomez E, Gonzàlez-Medina A, Hagège AA, Huang J, Katova T, Kiatchoosakun S, Kim KS, Kozan Ö, Llamas EB, Martinez F, Merkely B, Mendoza I, Mosterd A, Negrusz-Kawecka M, Peuhkurinen K, Ramires FJ, Refsgaard J, Rosenthal A, Senni M, Sibulo AS Jr, Silva-Cardoso J, Squire IB, Starling RC, Teerlink JR, Vanhaecke J, Vinereanu D, Wong RC,; PARADIGM-HF Investigators and Coordinators. Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. Circulation 2015; 131: 54-61.
80. Sanchis L, Andrea R, Falces C, Llopis J, Morales-Ruiz M, Lõpez-Sobrino T, Pérez-Villa F, Sitges M, Sabate M, Brugada J,. Prognosis of new-onset heart failure outpatients and collagen biomarkers. Eur J Clin Invest 2015; 45: 842-849.
81. Seliger SL, de Lemos J, Neeland IJ, Christenson R, Gottdiener J, Drazner MH, Berry J, Sorkin J, deFilippi C,. Older adults, 'malignant' left ventricular hypertrophy, and associated cardiac-specific biomarker phenotypes to identify the differential risk of new-onset reduced versus preserved ejection fraction heart failure: CHS (Cardiovascular Health Study). JACC Heart Fail 2015; 3: 445-455.
82. Lovelock JD, Monasky MM, Jeong EM, Lardin HA, Liu H, Patel BG, Taglieri DM, Gu L, Kumar P, Pokhrel N, Zeng D, Belardinelli L, Sorescu D, Solaro RJ, Dudley SC Jr., Ranolazine improves cardiac diastolic dysfunction through modulation of myofilament calcium sensitivity. Circ Res 2012; 110: 841-850.
83. Hwang H, Arcidi JM Jr, Hale SL, Simkhovich BZ, Belardinelli L, Dhalla AK, Shryock JC, Kloner RA,. Ranolazine as a cardioplegia additive improves recovery of diastolic function in isolated rate hearts. Circulation 2009; 120 (Suppl 11): S16-S21.
84. D'Elia E, Fiocca L, Ferrero P, Iacovoni A, Baio P, Medolago G, Duino V, Gori M, Gavazzi A, Senni M,. Ranolazine in heart failure with preserved left ventricular ejection fraction and microvascular dysfunction: case report and literature review. J Clin Pharmacol 2013; 53: 665-669
85. Metha PK, Goykhman P, Thomson LE, Shufelt C, Wei J, Yang Y, Gill E, Minissian M, Shaw LJ, Slomka PJ, Slivka M, Berman DS, Bairey Merz CN,. Ranolazine improves angina in women with evidence of myocardial ischemia but no obstructive coronary artery disease. J Am Coll Cardiol 2011; 4: 514-522.
86. Figueredo VM, Pressman GS, Romero-Corral A, Murdock E, Holderbach P, Morris DL, Improvement in left ventricular systolic and diastolic performance during ranolazine treatment in patients with stable angina. J Cardiovasc Pharm T 2011; 16: 168-172.
87. Jhund PS, Claggett BL, Voors AA, Zile MR, Packer M, Pieske BM, Kraigher-Krainer E, Shah AM, Prescott MF, Shi V, Lefkowitz M, McMurray JJ, Solomon SD,; PARAMOUNT investigators. Elevation in high sensitivity troponin T in heart failure and preserved ejection fraction and influence of treatment with the angiotensin receptor neprilysin inhibitor LCZ696. Circ Heart Fail 2014; 7: 953-959.
88. Braunwald E., The path to an angiotensin receptor antagonist-neprilysin inhibitor in the treatment of heart failure. J Am Coll Cardiol 2015; 17: 1029-1041.
89. Solomon SD, Zile M, Pieske B, Voors A, Shah A, Kraigher-Krainer E, Shi V, Bransford T, Takeuchi M, Gong J, Lefkowitz M, Packer M, McMurray JJ,; Prospective comparison of ARNI with ARB on Management Of heart failUre with preserved ejectioN fracTion (PARAMOUNT) Investigators. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet 2012; 20: 1387-395.
90. Ellis KL, Cameron VA, Troughton RW, Frampton CM, Ellmers LJ, Richards AM,. Circulating microRNAs as candidate markers to distinguish heart failure in breathless patients. Eur J Heart Fail 2013; 15: 1138-1147.
91. Watson CJ, Gupta SK, O'Connell E, Thum S, Glezeva N, Fendrich J, Gallagher J, Ledwidge M, Grote-Levi L, McDonald K, Thum T,. MicroRNA signatures differentiate preserved from reduced ejection fraction heart failure. Eur J Heart Fail 2015; 17: 405-415.
92. Schmitter D, Voors AA, van der Harst P,. HFpEF vs. HFrEF: can microRNAs advance the diagnosis? Eur J Heart Fail 2015; 17: 351-354.
93. Kalozoumi G, Yacoub M, Sanoudou D,. MicroRNAs in heart failure: small molecules with major impact. Glob Cardiol Sci Pract 2014; 2014: 79-102.
94. Wong LL, Armugam A, Sepramaniam S, Karolina DS, Lim KY, Lim JY, Chong JP, Ng JY, Chen YT, Chan MM, Chen Z, Yeo PS, Ng TP, Ling LH, Sim D, Leong KT, Ong HY, Jaufeerally F, Wong R, Chai P, Low AF, Lam CS, Jeyaseelan K, Richards AM,. Circulating microRNAs in heart failure with reduced and preserved left ventricular ejection fraction. Eur J Heart Fail 2015; 17: 393-404.
95. Nishikimi T, Kuwahara K, Nakagawa Y, Kangawa K, Nakao K,. Adrenomedullin in cardiovascular disease: a useful biomarker, its pathological roles and therapeutic application. Curr Protein Pept Sci 2013; 14: 256-267.
96. Brouwers FP, van Gilst WH, Damman K, van den Berg MP, Gansevoort RT, Bakker SJ, Hillege HL, van Veldhuisen DJ, van der Harst P, de Boer RA,. Clinical risk stratification optimizes value of biomarkers to predict new-onset heart failure in a community-based cohort. Circ Heart Fail 2014; 7: 723-731.
97. Yu CM, Cheung BM, Leung R, Wang Q, Lai WH, Lau CP,. Increase in plasma adrenomedullin in patients with heart failure characterized by diastolic dysfunction. Heart 2001; 86: 155-160.
98. Georgakopoulus D, Little WC, Abraham WT, Weaver FA, Zile MR,. Chronic baroreflex activation: approach to heart failure with preserved ejection fraction. J Card Fail 2011; 2; 167-178.